Anne Siri G.
- Country
- Norway
- Department
- Pulmanory Medicine Department
Research Overview
- Phase II Randomized Study of Atezolizumab Plus Chemoradiotherapy Versus Chemoradiotherapy Alone in Limited Disease Small-Cell Lung Cancer
- A randomized, phase II, open-label, multicenter study investigating efficacy and safety of anti-PD-1/PD-L1 treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer
Data & Insights
Has run more than one trial at 5 of 29 partner sites.
Specializations
Lung Cancer Research
The investigator specializes in advanced treatment approaches for lung cancer, with particular focus on both small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
- Limited Disease SCLC Management
- Advanced Stage NSCLC Treatment
- Stage IIIB/IIIC and IV NSCLC
Additional expertise includes concurrent treatment strategies and disease-specific interventions.
Immunotherapy Applications
The investigator focuses on innovative immunotherapy approaches in thoracic oncology, including the application of PD-1/PD-L1 inhibitors and novel vaccination strategies.
- Atezolizumab-based Therapy
- UV1 Vaccination Studies
- Combination Immunotherapy Protocols
Expertise extends to integrating immunotherapy with conventional treatment modalities.
Multimodal Treatment
The investigator explores combined therapeutic approaches, particularly the integration of chemoradiotherapy with novel agents in thoracic oncology.
- Concurrent Chemoradiotherapy
- Sequential Treatment Strategies
- First-line Treatment Optimization
Focus includes development of comprehensive treatment protocols for various stages of lung cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.